Allergan’s $750 Million Namenda Antitrust Settlement Approved

U.S. District Judge Colleen McMahon gave final approval to resolution of antitrust litigation over the Alzheimer’s drug after a very brief fairness hearing in federal court in Manhattan on Wednesday, during which no objections were raised

• Allergan said on the eve of trial in October that its Forest subsidiaries had reached resolution with a plaintiff class of direct Namenda purchasers; the settlement got preliminary approval later that month
• The plaintiffs, a pair of drug distributors, alleged Allergan violated antitrust laws by conspiring to delay the introduction of less expensive, generic versions of Namenda
• The case is In Re Namenda Direct ...